NCT00310674View on ClinicalTrials.gov

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2004

Conditions
Prevention of Meningococcal Infection
Interventions
BIOLOGICAL

Meningococcal C Conjugate Vaccine

Trial Locations (1)

20122

Istituto di Pediatria, Università degli Studi di Milano, Milan

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT00310674 - Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age | Biotech Hunter | Biotech Hunter